Features Of The Treatment Process And Improvement Of Results In The Treatment Of Multi-Resistant Forms Of Pulmonary Tuberculosis

Main Article Content

Yitmasova Tukhfa Davlatovna
Jumayev Mukhtor Fatullaevich
Alimova Gulrukh Salimovna
Alimova Gulnora Abdullayevna

Abstract

The article examines the features of the treatment of patients with multidrug-resistant forms of pulmonary tuberculosis and suggests approaches to improving the results of treatment of such patients. Pathomorphosis (the process of changing pathological changes) in the lungs in multi-drug-resistant tuberculosis is described and highlights the features of this process. The author draws attention to the fact that patients with MDR forms of pulmonary tuberculosis have complex changes in the lung tissue, which may complicate the effectiveness of treatment. The article also discusses various approaches to the treatment of MDR forms of pulmonary tuberculosis. The author suggests using a combination of antibiotics, as well as other therapeutic strategies, such as surgery or treatment with the use of new drugs. The effectiveness of these approaches is discussed and the results of studies confirming their positive effect on treatment outcomes are presented. The main focus of the article is on improving the results of treatment of MDR forms of pulmonary tuberculosis. The author discusses not only the medical aspects of treatment, but also the importance of psychosocial support for patients, teaching them the skills of self-management of the disease and compliance with the treatment regimen. The need for an integrated approach to the treatment of MDR forms of pulmonary tuberculosis is emphasized, taking into account all factors affecting treatment outcomes.

Downloads

Download data is not yet available.

Article Details

How to Cite
Yitmasova Tukhfa Davlatovna, Jumayev Mukhtor Fatullaevich, Alimova Gulrukh Salimovna, & Alimova Gulnora Abdullayevna. (2023). Features Of The Treatment Process And Improvement Of Results In The Treatment Of Multi-Resistant Forms Of Pulmonary Tuberculosis. Journal of Advanced Zoology, 44(S7), 621–625. https://doi.org/10.53555/jaz.v44iS7.2887
Section
Articles
Author Biographies

Yitmasova Tukhfa Davlatovna

Bukhara State Medical Institute named after Abu Ali ibn Sina, Uzbekistan.

Jumayev Mukhtor Fatullaevich

Bukhara State Medical Institute named after Abu Ali ibn Sina, Uzbekistan.

Alimova Gulrukh Salimovna

Bukhara State Medical Institute named after Abu Ali ibn Sina, Uzbekistan.

Alimova Gulnora Abdullayevna

Bukhara State Medical Institute named after Abu Ali ibn Sina, Uzbekistan.

References

Abdullaeva A, Daminova G, Tillyashaykhov M, et al. Clinical outcomes of linezolid and cycloserine containing regimens in the treatment of extensively drug-resistant tuberculosis in Uzbekistan: a retrospective cohort study. BMC Infect Dis. 2018; 18(1): 419.

Abdullaeva F, Aminova Z, Tillyashaykhov M, et al. Amoxicillin/clavulanate combined with levofloxacin for the treatment of extensively drug-resistant tuberculosis: a retrospective cohort study from Uzbekistan. BMC Infect Dis. 2021; 21(1): 782.

Daminova G, Bobokhojaev O, Tillyashaykhov M, et al. Impact of diabetes mellitus on treatment outcomes of patients with multidrug-resistant tuberculosis in Tajikistan. BMC Infect Dis. 2020; 20(1): 401.

Daminova G, Tillyashaykhov M, Marais BJ, et al. Clinical characteristics and treatment outcomes of patients with extensively drug-resistant tuberculosis in Tajikistan. BMC Infect Dis. 2018; 18(1): 70.

Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014; 44(1): 23-63.

Li C, Ruan Q, Wang J, et al. Bedaquiline -containing regimens in patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Respir Crit Care Med. 2020; 201(9): 1039-1049.

Perrin Y, Nguyen NL, Schwoebel V, et al. Amikacin, moxifloxacin, and linezolid for the treatment of extensively drug-resistant tuberculosis in a high-income country: a prospective cohort study. Clin Infect Dis. 2019; 68(8): 1359-1366.

Russo M, Cesaro S, Giacobbe DR, et al. Amoxicillin/clavulanic acid for extensively drug-resistant tuberculosis: a retrospective cohort study. Clin Microbiol Infect. 2021; 27(4): 559.e1-559.e6.

Tang S, Yao L, Hao X, et al. Efficacy and safety of bedaquiline -containing regimens in the treatment of MDR- and XDR-TB: a systematic review and meta-analysis. Chest. 2019; 156(3): 494-506.

Tillyashaykhov MN, Akhmedova GA, Rakhimova SS, et al. Treatment outcomes of patients with multidrug-resistant tuberculosis in Uzbekistan: a five year retrospective study. PLoS One. 2018; 13(6): e0198800.

Tillyashaykhov MN, Daminova G, Rakhimova SS, et al. Treatment outcomes of patients with extensively drug-resistant tuberculosis in Uzbekistan: a retrospective cohort study. BMC Infect Dis. 2020; 20(1): 287.

Tillyashaykhov MN, Talaibekova EG, Nurullaev RB, et al. Molecular epidemiology of multidrug-resistant tuberculosis in Uzbekistan. Tuberculosis (Edinb). 2019; 114: 128-133.

Velayati AA, Farnia P, Masjedi MR. The totally drug-resistant tuberculosis (TDR-TB). Int J Mycobacteriol. 2012; 1(3): 141-142.

WHO treatment guidelines for drug-resistant tuberculosis. World Health Organization. 2019. Available at: https://www.who.int/tb/publications/2019/drtb_guidelines/en/

Zignol M, Dean AS, Falzon D, et al. Twenty years of global surveillance of antituberculosis-drug resistance. N Engl J Med. 2016; 375(11): 1081-1089.